These findings not only position TFAM as a potential biomarker for glioma stratification but also highlight therapeutic opportunities tailored to metabolic subtype, such as targeting oxidative stress vulnerabilities in GPM-type GBMs or disrupting adaptive mitochondrial networks in MTC-type tumors. The gene discussed is TFAM; the disease is glioma.